Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

The plasminogen receptor, Plg-RKT, is essential for mammary lobuloalveolar development and lactation.

Miles LA, Baik N, Bai H, Makarenkova HP, Kiosses WB, Krajewski S, Castellino FJ, Valenzuela A, Varki NM, Mueller BM, Parmer RJ.

J Thromb Haemost. 2018 May;16(5):919-932. doi: 10.1111/jth.13988. Epub 2018 Apr 1.

PMID:
29495105
2.

Identification of the integrin-binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling.

Rothmeier AS, Liu E, Chakrabarty S, Disse J, Mueller BM, Østergaard H, Ruf W.

Blood. 2018 Feb 8;131(6):674-685. doi: 10.1182/blood-2017-02-768218. Epub 2017 Dec 15.

PMID:
29246902
3.

Targeting cancer-specific glycans by cyclic peptide lectinomimics.

Rodriguez MC, Yongye AB, Cudic M, Martinez Mayorga K, Liu E, Mueller BM, Ainsley J, Karabencheva-Christova T, Christov CZ, Cudic M, Cudic P.

Amino Acids. 2017 Nov;49(11):1867-1883. doi: 10.1007/s00726-017-2485-3. Epub 2017 Sep 11.

PMID:
28894966
4.

Deficiency of plasminogen receptor, Plg-RKT , causes defects in plasminogen binding and inflammatory macrophage recruitment in vivo.

Miles LA, Baik N, Lighvani S, Khaldoyanidi S, Varki NM, Bai H, Mueller BM, Parmer RJ.

J Thromb Haemost. 2017 Jan;15(1):155-162. doi: 10.1111/jth.13532. Epub 2016 Nov 28.

5.

New insights into the role of Plg-RKT in macrophage recruitment.

Miles LA, Lighvani S, Baik N, Parmer CM, Khaldoyanidi S, Mueller BM, Parmer RJ.

Int Rev Cell Mol Biol. 2014;309:259-302. doi: 10.1016/B978-0-12-800255-1.00005-3. Review.

6.

Combining cellular and gene therapy approaches for treatment of intracranial tumors.

Hickey MJ, Kasahara N, Mueller BM, Kruse CA.

Oncoimmunology. 2013 Oct 1;2(10):e25989. Epub 2013 Sep 12.

7.

Local adipocytes enable estrogen-dependent breast cancer growth: Role of leptin and aromatase.

Liu E, Samad F, Mueller BM.

Adipocyte. 2013 Jul 1;2(3):165-9. doi: 10.4161/adip.23645. Epub 2013 Jul 23.

8.

Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain.

Hickey MJ, Malone CC, Erickson KL, Lin A, Soto H, Ha ET, Kamijima S, Inagaki A, Takahashi M, Kato Y, Kasahara N, Mueller BM, Kruse CA.

Clin Cancer Res. 2013 Aug 1;19(15):4137-48. doi: 10.1158/1078-0432.CCR-12-3735. Epub 2013 Jun 18.

9.

Endothelial protein C receptor function in murine and human breast cancer development.

Schaffner F, Yokota N, Carneiro-Lobo T, Kitano M, Schaffer M, Anderson GM, Mueller BM, Esmon CT, Ruf W.

PLoS One. 2013 Apr 9;8(4):e61071. doi: 10.1371/journal.pone.0061071. Print 2013.

10.

Protein instability following transport or storage on dry ice.

Murphy BM, Swarts S, Mueller BM, van der Geer P, Manning MC, Fitchmun MI.

Nat Methods. 2013 Apr;10(4):278-9. doi: 10.1038/nmeth.2409. No abstract available.

PMID:
23538862
11.

Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development.

Schaffner F, Versteeg HH, Schillert A, Yokota N, Petersen LC, Mueller BM, Ruf W.

Blood. 2010 Dec 23;116(26):6106-13. doi: 10.1182/blood-2010-06-289314. Epub 2010 Sep 22.

12.

Hyaluronan inhibits postchemotherapy tumor regrowth in a colon carcinoma xenograft model.

Mueller BM, Schraufstatter IU, Goncharova V, Povaliy T, DiScipio R, Khaldoyanidi SK.

Mol Cancer Ther. 2010 Nov;9(11):3024-32. doi: 10.1158/1535-7163.MCT-10-0529. Epub 2010 Sep 10.

13.

RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods.

Bohmann K, Hennig G, Rogel U, Poremba C, Mueller BM, Fritz P, Stoerkel S, Schaefer KL.

Clin Chem. 2009 Sep;55(9):1719-27. doi: 10.1373/clinchem.2008.122572. Epub 2009 Jul 17.

14.

FAPP2 gene downregulation increases tumor cell sensitivity to Fas-induced apoptosis.

Tritz R, Hickey MJ, Lin AH, Hadwiger P, Sah DW, Neuwelt EA, Mueller BM, Kruse CA.

Biochem Biophys Res Commun. 2009 May 29;383(2):167-71. doi: 10.1016/j.bbrc.2009.03.126. Epub 2009 Mar 31.

15.

siRNA Down-regulation of the PATZ1 Gene in Human Glioma Cells Increases Their Sensitivity to Apoptotic Stimuli.

Tritz R, Mueller BM, Hickey MJ, Lin AH, Gomez GG, Hadwiger P, Sah DW, Muldoon L, Neuwelt EA, Kruse CA.

Cancer Ther. 2008;6(B):865-876.

16.

Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice.

Versteeg HH, Schaffner F, Kerver M, Ellies LG, Andrade-Gordon P, Mueller BM, Ruf W.

Cancer Res. 2008 Sep 1;68(17):7219-27. doi: 10.1158/0008-5472.CAN-08-0419.

17.

Inhibition of tissue factor signaling suppresses tumor growth.

Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W.

Blood. 2008 Jan 1;111(1):190-9. Epub 2007 Sep 27.

18.

Akt plays an important role in breast cancer cell chemotaxis to CXCL12.

Zhao M, Mueller BM, DiScipio RG, Schraufstatter IU.

Breast Cancer Res Treat. 2008 Jul;110(2):211-22. Epub 2007 Aug 9.

PMID:
17687643
19.

Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis.

Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, Andrade-Gordon P, Friedlander M, Ruf W.

Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1456-62. Epub 2007 Mar 15.

PMID:
17363687
20.

Disulfide isomerization switches tissue factor from coagulation to cell signaling.

Ahamed J, Versteeg HH, Kerver M, Chen VM, Mueller BM, Hogg PJ, Ruf W.

Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):13932-7. Epub 2006 Sep 7.

21.

Breaking the one antibody-one target axiom.

Guo F, Das S, Mueller BM, Barbas CF 3rd, Lerner RA, Sinha SC.

Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11009-14. Epub 2006 Jul 5.

22.

Thrombin generation and the pathogenesis of cancer.

Ruf W, Mueller BM.

Semin Thromb Hemost. 2006 Apr;32 Suppl 1:61-8. Review.

PMID:
16673267
23.

Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways.

Liu Y, Mueller BM.

Biochem Biophys Res Commun. 2006 Jun 16;344(4):1263-70. Epub 2006 Apr 19.

PMID:
16650817
24.

Estrogen induces lung metastasis through a host compartment-specific response.

Banka CL, Lund CV, Nguyen MT, Pakchoian AJ, Mueller BM, Eliceiri BP.

Cancer Res. 2006 Apr 1;66(7):3667-72.

25.
26.

Breast cancer cell lines grown in vivo: what goes in isn't always the same as what comes out.

Jessani N, Niessen S, Mueller BM, Cravatt BF.

Cell Cycle. 2005 Feb;4(2):253-5. Epub 2005 Feb 21.

PMID:
15655359
27.

Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo.

Jessani N, Humphrey M, McDonald WH, Niessen S, Masuda K, Gangadharan B, Yates JR 3rd, Mueller BM, Cravatt BF.

Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13756-61. Epub 2004 Sep 8.

28.

Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis.

Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM.

Mol Cancer Res. 2004 Jul;2(7):395-402.

29.

Regulation of angiogenesis by tissue factor cytoplasmic domain signaling.

Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W.

Nat Med. 2004 May;10(5):502-9. Epub 2004 Apr 18.

PMID:
15098027
30.

Activation of endothelial cell protease activated receptor 1 by the protein C pathway.

Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W.

Science. 2002 Jun 7;296(5574):1880-2.

31.

Integrin activation controls metastasis in human breast cancer.

Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM.

Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1853-8.

32.

Diverse functions of protease receptor tissue factor in inflammation and metastasis.

Ruf W, Fischer EG, Huang HY, Miyagi Y, Ott I, Riewald M, Mueller BM.

Immunol Res. 2000;21(2-3):289-92. Review.

PMID:
10852129
33.

Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor.

Ott I, Miyagi Y, Miyazaki K, Heeb MJ, Mueller BM, Rao LV, Ruf W.

Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):874-82.

PMID:
10712416
34.

Tissue factor signaling.

Ruf W, Mueller BM.

Thromb Haemost. 1999 Aug;82(2):175-82. Review. No abstract available.

PMID:
10605702
35.

Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor.

Fischer EG, Riewald M, Huang HY, Miyagi Y, Kubota Y, Mueller BM, Ruf W.

J Clin Invest. 1999 Nov;104(9):1213-21. Erratum in: J Clin Invest 2000 Feb;105(3):395.

36.
37.
38.

Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy.

Dolman CS, Mueller BM, Lode HN, Xiang R, Gillies SD, Reisfeld RA.

Clin Cancer Res. 1998 Oct;4(10):2551-7.

39.
41.

A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280.

Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W.

J Cell Biol. 1998 Mar 9;140(5):1241-53.

42.

Alphav integrins mediate adhesion and migration of breast carcinoma cell lines.

Wong NC, Mueller BM, Barbas CF, Ruminski P, Quaranta V, Lin EC, Smith JW.

Clin Exp Metastasis. 1998 Jan;16(1):50-61.

PMID:
9502077
43.
44.
45.
46.

Proteases and protease inhibitors in tumor progression.

DeClerck YA, Imren S, Montgomery AM, Mueller BM, Reisfeld RA, Laug WE.

Adv Exp Med Biol. 1997;425:89-97. Review.

PMID:
9433492
47.

Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.

Yebra M, Parry GC, Strömblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA.

J Biol Chem. 1996 Nov 15;271(46):29393-9.

48.

Tissue factor in cancer angiogenesis and metastasis.

Ruf W, Mueller BM.

Curr Opin Hematol. 1996 Sep;3(5):379-84. Review.

PMID:
9372105
49.

Different roles for plasminogen activators and metalloproteinases in melanoma metastasis.

Mueller BM.

Curr Top Microbiol Immunol. 1996;213 ( Pt 1):65-80. Review.

PMID:
8814995
50.

Supplemental Content

Loading ...
Support Center